MA29498B1 - Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1 - Google Patents

Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1

Info

Publication number
MA29498B1
MA29498B1 MA30441A MA30441A MA29498B1 MA 29498 B1 MA29498 B1 MA 29498B1 MA 30441 A MA30441 A MA 30441A MA 30441 A MA30441 A MA 30441A MA 29498 B1 MA29498 B1 MA 29498B1
Authority
MA
Morocco
Prior art keywords
beta
adrenergic receptor
receptor kinase
kinase inhibitors
pyrazolopyridine derivatives
Prior art date
Application number
MA30441A
Other languages
English (en)
Inventor
Henning Steinhagen
Jochen Huber
Kurt Ritter
Bernard Pirard
Kirsten Bjergarde
Marcel Patek
Martin Smrcina
Linli Wei
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29498B1 publication Critical patent/MA29498B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVES DE PYRAZOLOPYRIDINE EN TANT QU'INHIBITEURS DE RECEPTEUR KINASE BETA-ADRENERGIQUE 1 L'invention concerne des dérivés de pyrazolopyridine 6-amido-substitués de formule (I) utiles en tant qu'inhibiteurs de récepteur kinase 1 bêta-adrénergique ((bêta)ARK-1), des compositions contenant de tels composés et leur utilisation pour le traitement et la prévention de l'insuffisance cardiaque chronique, l'hypertension, l'ischémie myocardique et les infections par le virus de l'hépatite C (VHC), et pour la prévention de l'addiction aux opiacés.
MA30441A 2005-06-27 2007-11-30 Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1 MA29498B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05013774 2005-06-27

Publications (1)

Publication Number Publication Date
MA29498B1 true MA29498B1 (fr) 2008-05-02

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30441A MA29498B1 (fr) 2005-06-27 2007-11-30 Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1

Country Status (30)

Country Link
US (1) US7910602B2 (fr)
EP (1) EP1899333B1 (fr)
JP (1) JP5010594B2 (fr)
KR (1) KR20080020638A (fr)
CN (1) CN101208340B (fr)
AR (1) AR054514A1 (fr)
AT (1) ATE423118T1 (fr)
AU (1) AU2006264044A1 (fr)
BR (1) BRPI0612320A2 (fr)
CA (1) CA2611296A1 (fr)
CY (1) CY1110464T1 (fr)
DE (1) DE602006005242D1 (fr)
DK (1) DK1899333T3 (fr)
ES (1) ES2322197T3 (fr)
HR (1) HRP20090244T2 (fr)
IL (1) IL188381A0 (fr)
MA (1) MA29498B1 (fr)
MX (1) MX2007015829A (fr)
MY (1) MY139016A (fr)
NO (1) NO20080392L (fr)
NZ (1) NZ564757A (fr)
PL (1) PL1899333T3 (fr)
PT (1) PT1899333E (fr)
RS (1) RS50821B (fr)
RU (1) RU2415855C2 (fr)
SI (1) SI1899333T1 (fr)
TW (1) TW200800982A (fr)
UY (1) UY29632A1 (fr)
WO (1) WO2007000241A1 (fr)
ZA (1) ZA200709853B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2009107391A1 (fr) * 2008-02-27 2009-09-03 武田薬品工業株式会社 Composé contenant un cycle aromatique à 6 chaînons
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (fr) 2013-03-15 2016-11-29 Pfizer Inc. Composes indoliques activant l'ampk
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
US12187723B2 (en) 2019-05-09 2025-01-07 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN114761404B (zh) 2019-10-01 2025-02-21 百时美施贵宝公司 经取代的双环杂芳基化合物
JP7545467B2 (ja) 2019-10-04 2024-09-04 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
EP4638420A1 (fr) * 2022-12-20 2025-10-29 Exelixis, Inc. Composés qui inhibent pkmyt1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ284846A (en) * 1994-06-16 1998-12-23 Pfizer 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
ZA9811178B (en) * 1997-12-13 2000-06-07 Bristol Myers Squibb Co Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
WO2003068773A1 (fr) * 2002-02-12 2003-08-21 Glaxo Group Limited Derives de pyrazolopyridine
EA200500322A1 (ru) * 2002-08-07 2005-08-25 Мицубиси Фарма Корпорейшн Соединения дигидропиразолопиридина
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체

Also Published As

Publication number Publication date
US7910602B2 (en) 2011-03-22
WO2007000241A1 (fr) 2007-01-04
JP5010594B2 (ja) 2012-08-29
ATE423118T1 (de) 2009-03-15
AR054514A1 (es) 2007-06-27
DK1899333T3 (da) 2009-06-15
TW200800982A (en) 2008-01-01
NO20080392L (no) 2008-02-28
RU2415855C2 (ru) 2011-04-10
EP1899333B1 (fr) 2009-02-18
MX2007015829A (es) 2008-02-22
JP2008543957A (ja) 2008-12-04
RU2008102970A (ru) 2009-08-10
ES2322197T3 (es) 2009-06-17
SI1899333T1 (sl) 2009-08-31
CN101208340A (zh) 2008-06-25
AU2006264044A1 (en) 2007-01-04
IL188381A0 (en) 2008-04-13
HRP20090244T2 (hr) 2009-07-31
ZA200709853B (en) 2008-12-31
HRP20090244T1 (en) 2009-06-30
BRPI0612320A2 (pt) 2010-11-09
CN101208340B (zh) 2010-12-22
EP1899333A1 (fr) 2008-03-19
UY29632A1 (es) 2007-01-31
CA2611296A1 (fr) 2007-01-04
KR20080020638A (ko) 2008-03-05
RS50821B (sr) 2010-08-31
PT1899333E (pt) 2009-04-23
DE602006005242D1 (de) 2009-04-02
MY139016A (en) 2009-08-28
US20080227777A1 (en) 2008-09-18
PL1899333T3 (pl) 2009-07-31
NZ564757A (en) 2009-12-24
CY1110464T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
MA29498B1 (fr) Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA29926B1 (fr) Derives de pyrazine
MA32231B1 (fr) Composés organiques
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31419B1 (fr) Derives de pyridine
MA32965B1 (fr) Derives de sulfonamides
TNSN07022A1 (fr) Derives de pyridine
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31766B1 (fr) Composés organiques
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.